Alterations in Gene Expression and Sensitivity to Genotoxic Stress Following HdmX or Hdm2 Knockdown in Human Tumor Cells Harboring Wild-Type p53 by Heminger, Katherine et al.
Wright State University 
CORE Scholar 
Biochemistry and Molecular Biology Faculty 
Publications Biochemistry and Molecular Biology 
1-2009 
Alterations in Gene Expression and Sensitivity to Genotoxic Stress 
Following HdmX or Hdm2 Knockdown in Human Tumor Cells 
Harboring Wild-Type p53 
Katherine Heminger 
Michael P. Markey 
Wright State University - Main Campus, michael.markey@wright.edu 
Meldrick Mpagi 
Steven J. Berberich 
Wright State University - Main Campus, steven.berberich@wright.edu 
Follow this and additional works at: https://corescholar.libraries.wright.edu/bmb 
 Part of the Molecular Biology Commons 
Repository Citation 
Heminger, K., Markey, M. P., Mpagi, M., & Berberich, S. J. (2009). Alterations in Gene Expression and 
Sensitivity to Genotoxic Stress Following HdmX or Hdm2 Knockdown in Human Tumor Cells Harboring 
Wild-Type p53. Aging, 1 (1), 89-108. 
https://corescholar.libraries.wright.edu/bmb/12 
This Article is brought to you for free and open access by the Biochemistry and Molecular Biology at CORE Scholar. 
It has been accepted for inclusion in Biochemistry and Molecular Biology Faculty Publications by an authorized 










































Only half of all human tumors contain mutations in the 
p53 tumor suppressor gene [1], with the other half 
retaining wild-type p53 but possessing defects in the 
expression of p53 regulatory proteins and pathways.  
Under non-stress conditions, p53 protein is maintained 
at a low basal level by constant ubiquitination and 
proteasomal degradation [2]. Upon DNA damage or 
various types of cellular stress, p53 is stabilized and 
functions as a transcription factor to induce genes 
involved in cell cycle arrest, apoptosis, and DNA repair 
[3].  The stringent regulation of p53 involves a complex  
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activated  upon  HdmX/2  knockdown.  Interestingly,  a  second  set  of  genes,  normally  transactivated  by  E2F1  as  cells
transverse  the G1‐S phase boundary, were  found  repressed  in a p21‐dependent manner  following HdmX/2 knockdown.
Taken together, these results provide novel insights into the reactivation of p53 in cells overexpressing HdmX and Hdm2.  
 
network of proteins, and is critical for maintaining 
genomic stability and suppressing tumor formation.   
 
Hdm2 and its structural homologue HdmX represent 
two essential negative regulators of p53 as 
demonstrated by their embryonic lethality in knockout 
mice and subsequent rescue by concurrent elimination 
of p53 [4].  Hdm2 inactivates p53 function through 
direct association resulting in an inhibition of 
transactivation [5] and, through its E3 ligase activity 
targeting p53, by ubiquitin-mediated proteasome 
degradation [6, 7]. While HdmX shows conservation in 
the Hdm2 E3 ligase ring finger domain through which it 
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can heterodimerize with Hdm2 [8, 9], HdmX lacks the 
ability to ubiquitinate p53 in vivo [10, 11] and thus can 
only antagonize p53 transactivation [12]. The 
heterodimerization of Hdm2 and HdmX also plays a 
critical role in the response to DNA damage enabling 
Hdm2 to promote the ubiquitination and rapid 
proteasomal degradation of HdmX, thereby facilitating 
the tumor suppressor activity of p53 [13-15].   Thus, the 
interactions between p53, Hdm2 and HdmX are critical 
for complete regulation of p53 [4]. 
 
The overexpression of either Hdm2 or HdmX can 
inhibit the activity of p53 and directly contribute to 
tumor formation.  It is not surprising that either one or 
both proteins are found overexpressed in many human 
tumors and tumor cell lines which harbor wild-type p53 
[16].  Diverse approaches to activate the wild-type p53 
in these tumors include the use of small molecule 
antagonists like Nutlin to inhibit the Hdm2-p53 
interaction [17-19], and the use of antisense 
oligonucleotides, antibodies, and small interfering 
RNAs directed at Hdm2 or HdmX [20-23].  Recent 
findings suggest that Hdm2 and HdmX are specific 
independent therapeutic targets for activating wild-type 
p53 and that anti-cancer approaches that target both 
Hdm2 and HdmX should be considered as a means of 
treatment for tumors [16, 18, 24].   
 
This study undertook an examination of gene 
expression alterations and the biological effects 
resulting from RNAi silencing of HdmX and Hdm2 in a 
breast cancer cell line overexpressing both proteins. 
Unlike previous studies examining only the biological 
effect of either HdmX or Hdm2 loss, this study focuses 
on a cell line where both proteins are overexpressed and 
further compliments those previous studies with a 
systematic examination of gene expression changes 
following loss of HdmX or Hdm2.  Interestingly, only 
p53 target genes primarily associated with cell cycle 
arrest were induced.  More striking was the repression 
of a large group of E2F-regulated genes upon HdmX/2 
knockdown.  Using siRNA approaches targeting p21, 
we were able to show that these E2F-regulated genes 
were repressed through p53 activation of p21.  
Furthermore, cell proliferation and colony formation 
assays confirmed that loss of HdmX or Hdm2 inhibited 
tumor cell growth and could sensitize these cells to 
treatment with doxorubicin. Taken together, these 
results suggest that in cells where both Hdm2 and 
HdmX are overexpressed, removal of one leads to an 
anti-proliferative effect in tumor cells harboring wild-
type p53 and induction of p53 cell cycle arrest genes 





RNAi knockdown of Hdm2 and HdmX in MCF7 
cells 
 
Given that HdmX and Hdm2 are overexpressed in 
approximately 17% of human tumors [16] the majority 
of which possess wild-type p53, this study set out to 
examine how loss of Hdm2/X affected gene expression 
and tumor cell growth.  MCF7, which possess wild-type 
p53 [25] and elevated levels of both HdmX and Hdm2 
(Figure 1A) was the tumor cell line used in these 
studies. To inactivate HdmX and Hdm2 we employed 
siRNA targeting each gene as described in the materials 
and methods.   
 
Before performing the Affymetrix GeneChip 
experiments we developed a triple transfection protocol 
that led to over 90% of the MCF7 cells taking up the 
siRNA (data not shown). Next, the effectiveness of the 
knockdown was assessed using RT-qPCR (data not 
shown) and Western blotting. Following the triple 
transfection protocol HdmX and p53 protein levels were 
undetectable with Hdm2 showing a greater than 80% 
reduction in protein expression (Figure 1B). As 
expected, the loss of either HdmX or Hdm2 led to an 
increase in the levels of p21. This p21 increase is p53-
dependent since no increase in p21 protein levels was 
detected upon concurrent knockdown of HdmX and 
p53.  While it has been suggested that Hdm2 controls 
the levels of p53 in non-stressed cells [26, 27], in our 
hands MCF7 cells showed only a slight increase in p53 
protein levels following the combined loss of HdmX 
and Hdm2. The inability of Hdm2 knockdown to result 
in an increase in p53 protein could be the result of 
MCF7 cells harboring an elevated level of HdmX.  
Consistent with this suggestion, the treatment of MCF7 
cells with Nutlin leads to increased p53 protein levels 
through loss of Hdm2 binding to p53 and concurrent 
Hdm2 mediated degradation of HdmX [28].  
 
Loss of Hdm2 and HdmX triggers inhibition of cell 
growth  
 
Other groups have reported that in cells where wild-type 
p53 is kept in check by overexpression of HdmX or 
Hdm2, their inhibition can trigger alterations in cell 
growth [29] and in some conditions apoptosis [30]. To 
assess the growth properties of RNAi knockdown of 
p53 regulators Hdm2 and HdmX, siRNA-transfected 
MCF7 cells were plated at low density in 6 well plates 
and allowed to grow for an additional 10 days.  While 
transfection of siCon or sip53 resulted in only minimal 
changes in cell growth (Figure 2B), knockdown of  either 
 
  











































HdmX or Hdm2, alone or in combination led to 
significantly fewer colonies (Figure 2A) and suppressed 


























































decrease in colony formation correlated with an increase 
in G1 arrest and not apoptosis (i.e. sub-G1) as 
determined by flow cytometry (data not shown).  
  
































Loss of HdmX or Hdm2 sensitizes MCF7 cells to 
DNA damage 
 
Several recent studies using Nutlin and various DNA 
damaging agents reported that blocking Mdm2:p53 
association led to increased chemosensitivity to DNA 
damaging agents [31, 32]. To examine whether 
knockdown of HdmX and Hdm2 can also elicit 
increased cytotoxicity to DNA damage, MCF7 cells 
were transfected with the indicated siRNA leading to 
alterations of gene expression (Figure 3B). Cells were 
then treated with varying doses of doxorubicin and cell 
viability assessed.  siRNAs targeting HdmX or Hdm2 
increased doxorubicin cytotoxicity, while removing 
both HdmX and Hdm2 led to the greatest level of 
chemosensitivity (Figure 3A).  Enhanced chemo-
sensitivity was also observed in cisplatin treatment of 
siHdmX or siHdm2 MCF7 cells (data not shown). 
 
Gene expression profiles of MCF7 cells lacking 
HdmX or Hdm2 
 
Having established an effective knockdown approach 
with effects on cell growth and increased sensitivity to 
DNA damage, we performed an Affymetrix GeneChip 
experiment to assess how loss of HdmX or Hdm2 
affected global gene expression in MCF7 cells. Each 
RNAi transfection was performed in three separate bio-
logical replicates.  The data analysis was carried out 
using GeneSpring GX software. Given the similarity of 
biological function uncovered in the previous experi-
ments we focused our informatics on genes commonly 
altered following RNAi treatment with siHdmX or 
siHdm2. In summary, .cel files were normalized using 
GCRMA, genes filtered by ANOVA and fold change, 
and genes significantly altered by both siHdmX and 
siHdm2 but not siHdmX + sip53 identified (see materials 
and methods for detailed approach).  From this approach 
we uncovered 394 gene alterations common to 
knockdown of both siHdmX and siHdm2 (Table 1). 
 
p53 activation following loss of HdmX or Hdm2 
triggers growth repressive genes 
Figure  2.  Loss  of  HdmX  and/or  Hdm2  inhibits MCF7
colony  formation.  (A) Following  siRNA  transfections, MCF7
cells were  seeded at 500 cells/well  in 6‐well plates. The cells
were  allowed  to  grow  for  ten  days  then  the  colonies were
stained with  crystal  violet.  Significantly  fewer  colonies were
present following knockdown of HdmX and/or Hdm2. The cells
transfected  with  sip53  or  a  non‐targeting  control  (siCon)
showed minimal effects on colony  formation  relative  to non‐
transfected control (Con/Control). (B) The percent cell growth
relative to untransfected control was determined by extracting
the  stain  in  10%  acetic  acid  and  quantifying  the  stain  by
reading absorbance at 590 nm. 
 
The initial examination of the 394 genes focused on 
those genes (n=222) that were increased following 
siHdmX or siHdm2 treatment relative to siCon.  
Thirteen genes were identified that were known p53-
regulated genes (Figure 4).  As expected these genes 
increased with siHdmX or siHdm2 treatment but had 
expression levels comparable or lower than siCon when 
treated with siHdmX+sip53 or sip53.  Interestingly, 
with the exception of Fas, this list of p53 target genes 
consisted predominately of genes encoding proteins 
involved in cell cycle arrest or DNA repair. Consistent 
with a model whereby p53 proapoptotic target genes 
require p53 that is phosphorylated at serine 46 by 
HIPK2 [33-35], we observed no detectable 
phosphorylation at serines 6, 15, 20, 46, or 392 
following the RNAi transfection protocol employed in 
these studies (data not shown). 
 
To confirm these results, we performed RT-qPCR using 
TaqMan primers targeting five known p53 target genes, 
three of which were identified in our analysis.  p21, 
BTG2 and ACTA2 are p53 target genes that are 
associated with cell cycle arrest or growth inhibition 
[36-38], while Hdm2 is a negative regulator of p53 and 
Noxa a pro-apoptotic factor  not observed  in our list  of  
  

























altered genes [39].  MCF7 cells were either mock 
transfected (Mock), transfected with siRNA that does 
not target any human gene (siCon) or transfected with 
siRNA to HdmX or Hdm2 either alone or in 
combination. The results in Figure 5 demonstrate that 
relative to siCon, knockdown of HdmX led to 
significant increases in hdm2, p21, BTG2 and ACTA2 
gene expression.  No significant change in gene 
expression was observed with Noxa, which is consistent 
with our GeneChip results.  With the obvious exception 
of hdm2, siRNA-targeting Hdm2 led to similar 
alterations in gene expression (Figure 5).  Finally, when 
both HdmX and Hdm2 were eliminated, the levels of 
the cell cycle arrest genes p21, BTG2 and ACTA2 
increased either synergistically or additively while 
levels of Noxa remained unchanged.  These results 
validate our GeneChip data that p53-target genes were 
induced upon HdmX or Hdm2 knockdown and that 
several of these genes encode proteins involved in the 
cell cycle arrest.   
 
p53 upregulation of p21 leads to global repression of 
E2F regulated genes 
 
After searching for genes that were directly upregulated 
by p53 we next evaluated those genes that were 
repressed (N=172) following HdmX and Hdm2 
knockdown (Figure 7).  Within the list of 
downregulated genes were a set of genes that encode 
proteins involved in G1-S phase transition, the majority 
of which were known E2F1 regulated genes.  It is 
known that p21 can inhibit CDK/cyclins involved in Rb 
phosphorylation [40] and within the literature we 
initially uncovered two reports where p53 activation led 
to repression of TERT or Chk2, two known E2F-
regulated genes [41, 42].  To determine whether 
repression of these genes was the result of an HdmX or 
Hdm2-dependent p53 activation, MCF7 cells were 
treated with siHdm2 or siHdmX alone or in 
combination with sip21.  RNA was isolated and RT-
qPCR performed to monitor relative expression of 
cyclin A2 (CCNA2), p21 and E2F1.  While E2F1 did 
not make the 394 gene list, it possesses an E2F1 DNA 
binding site [43]. Relative expression for each of the 
genes was normalized to GAPDH.  As expected, loss of 








Figure  3. Knockdown  of HdmX  enhances doxorubicin‐induced  cytotoxicity.  (A)  Percent  cell  viability  relative  to  untransfected
untreated  control  cells. MCF7  cells were  treated with  doxorubicin  (0.25‐1.0  μg/mL)  for  48  hours  and  cell  viability was  determined  by
absorbance at 590 nm. The loss of HdmX and/or Hdm2 showed an enhanced cytotoxicity relative to control cells. (B) RT‐qPCR analysis of




concomitant decrease in both CCNA2 and E2F1 (Figure 
7).  In contrast, loss of Hdm2/X and p21 completely 
abrogated CCNA2 and E2F1 repression consistent with 












Figure  4.  GeneChip  expression  of  13  known  p53‐
regulated  genes  that were  induced  by  knockdown  of
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DISCUSSION 
 
As an essential tumor suppressor it is no surprise that 
human tumors demonstrate a diverse array of genetic 
mechanisms to inactivate p53 function.  Central to this 
present study are tumors where one or both of the 
negative regulators of p53, Hdm2 and HdmX, are 
overexpressed leading to loss of p53 activity.  Previous 
studies have focused on Hdm2 overexpression, where a 
small molecule inhibitor Nutlin 3 has proven to activate 
wild-type p53 in cell lines with elevated Hdm2, 
triggering apoptosis when combined with genotoxic 
agents that do not function as anti-mitotics [44].  
Unfortunately, Nutlins have not proven as effective in 
tumors where HdmX is overexpressed [18, 45-47], 
suggesting the need for additional approaches aimed at 
blocking the HdmX:p53 association particularly given 



























Here we have employed RNAi approaches and DNA 
microarrays to better understand the activation of p53 in 
cells overexpressing Hdm2 and HdmX.  In MCF7 cells 
a growth arrest with no detectable apoptosis was 
observed following knockdown of either Hdm2 or 
HdmX (Figure 2 and data not shown).  While loss of 
either HdmX or Hdm2 was sufficient to trigger an anti-
proliferative effect, the combined loss of both HdmX 






 Figure  6.  GeneChip  expression  of  13  reported  E2F1‐
regulated genes that were repressed by knockdown of










Even though this RNAi approach appears to activate 
p53 without triggering its phosphorylation (data not 
shown), the loss of either HdmX or Hdm2 did 
effectively sensitize the cells to doxorubicin with the 
loss of both Hdm2 and HdmX being most sensitive to 
DNA damage (Figure 3).  Surprisingly our results 
showed only a modest elevation of endogenous p53 
levels following loss of HdmX and Hdm2 (Figure 1).  
This result maybe unique to MCF7 cells which harbor 
elevated Hdm2 and HdmX, in contrast to most tumor 
cell lines with wild-type p53 that possessed only 
elevated Hdm2 (Figure 1A).   Consistent with the need 
for only one negative regulator to be elevated 65% of 
retinoblastoma tumors overexpress HdmX and possess 
wild-type p53 [48]. Based on our previous HdmX 
overexpression studies [10] we would predict that the 
overexpression of HdmX might inhibit Hdm2 
degradation of p53 in MCF7 cells and thus could 
explain why modulating Hdm2 levels in MCF7 cells has 
no dramatic effect on p53 levels. 
Figure  5.  RT‐qPCR  validation  of  siRNA  knockdown  in
MCF7 cells. (A) The hdmX, hdm2, and p21 mRNA expression
relative  to  siCon  (non‐targeting  siRNA)  is  shown.  The  p21
transcript  is  induced  following  loss  of  HdmX  or  Hdm2,  and
synergistically induced following loss of both HdmX and Hdm2.
(B)  BTG2,  ACTA2,  and  NOXA  mRNA  expression  relative  to
untransfected control  (Con). The p53  target genes, BTG2 and
ACTA2, are  induced by  loss of HdmX and/or Hdm2, while  the
expression of the proapoptotic gene, NOXA, is not altered. 
 
The DNA microarray experiment directly tested 
whether HdmX or Hdm2 knockdown triggered an 
increase in p53-regulated genes. While 394 genes were 
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significantly altered by either HdmX or Hdm2 
knockdown (Table 1), only a small group was 
previously identified p53 targets (Figure 4).  A few of 
the remaining genes induced by HdmX or Hdm2 loss 
are likely novel p53 regulated genes (S. Berberich, 
personal communication) but most probably represent 
downstream effects of the cell cycle arrest induced by 
p53.  Within the 13 identified p53 target genes it is 
noteworthy that only one apoptotic gene (Fas) was 
found activated by loss of either HdmX or Hdm2. Upon 
careful examination of 16 known p53 pro-apoptotic 
genes we found that several of them were repressed 
following p53 knockdown, suggesting that their failure 
to be induced by loss of HdmX or Hdm2 was not a cell-
type specific phenotype. Rather, we propose that the 
non-genotoxic release of p53 from Hdm2 of HdmX 
results in a preferential activation of growth arrest target 
genes, like p21 (Figure 5).  This model is consistent 
with recent work suggesting that p53 promoter selection 


















Another interesting finding within the microarray data 
was a subgroup of genes that were repressed upon 
HdmX and Hdm2 knockdown and could be classified as 
known E2F-regulated genes. Other groups have noted 
that p53 activation of p21 could lead to the repression of 
TERT [42] or Chk2 [41], known E2F-target genes, and 
another group recently reported similar findings using 
microarray assays [50].    
While this report focused on genes commonly regulated 
by HdmX and Hdm2, it is worth mentioning that within 
genes uniquely regulated by either HdmX or Hdm2 we 
did not observe any additional p53 regulated genes (M. 
Markey, personal communication). The common 
biological effects of HdmX or Hdm2-loss and 
significant overlap of gene expression patterns are in 
contrast to recent in vivo studies where the knockout of 
Mdm2 or MdmX in adult mouse tissues lead to non-
overlapping roles in regards to regulating p53 activity 
[51].  We believe these findings point to either 
differences in cell culture verses tissue studies or more 
likely represent a significant departure in the roles that 
Hdm2 and HdmX play when expressed at physiological 
levels compared to the elevated levels in tumor cells.  
 
Finally these studies demonstrate that non-genotoxic 
activation of p53 by knockdown of its inhibitors Hdm2 
and HdmX leads to the induction of genes involved in 
cell-cycle arrest, as well as repression of genes along 
the E2F/Rb pathway that promote cell cycle entry. 
These alterations in gene expression resulted in a 
decreased population of proliferative cells without 
necessarily increasing apoptosis.  A non-genotoxic 
activation of p53 is one possible mechanism for the 
reduction in cellular proliferation observed during 
aging. This further underscores the critical importance 
of tumor suppressor activation in senescence and 
organismal aging.   
 
MATERIALS AND METHODS 
 
Cell lines, antibodies, siRNA and chemotherapeutic 
agents. The human breast tumor cell line MCF7 was 
grown in Dulbecco’s modified Eagle medium (DMEM) 
supplemented with 10% bovine growth serum (BGS), 
and 10 µg/ml gentamicin unless otherwise indicated.  
HdmX polyclonal antibody (Bethyl Laboratories, Inc.), 
p21 polyclonal antibody C-19 (Santa Cruz 
Biotechnology, Inc.), p53 monoclonal antibody Ab-6 
(Oncogene), Hdm2 monoclonal antibody SMP-14 
(Santa Cruz Biotechnology, Inc.) and beta-actin 
monoclonal antibody (Sigma, Inc.) were used as 
indicated.  A phosphorylation-specific p53 polyclonal 
antibody kit (Cell Signaling Technology, Inc.) was 
utilized per manufacturer’s protocol.  Horseradish 
peroxidase (HRP)-conjugated anti-mouse or anti-rabbit 
secondary antibodies (Promega) were used with Super 
Signal substrate (Pierce) for chemiluminescence 
detection of proteins.    siGENOME duplex RNA 
targeting mRNA from hdmX, hdm2, or p53, and a non-
targeting control siRNA were obtained from 
Dharmacon Research, Inc. and siRNA transfection was 
performed using Oligofectamine or Lipofectamine 2000 
(Invitrogen) as described below.  Doxorubicin hydro-
Figure 7. Repression of E2F1‐regulated genes by Hdm2
or  HdmX  knockdown  is  blocked  by  concurrent
knockdown of p21.   MCF7  cells were  transfected with  the
indicated  siRNA combinations.   Twenty‐four hours  later, RNA
was  isolated and subjected to RT‐qPCR to quantify expression
of  CCNA2,  p21  and  E2F1  after  normalization  to  GAPDH.
Expression  levels  (Y‐axis) were  relative  to siCon and  reported
as  RQ  values.    Error  bars  represent  the  95%  confidence
interval of the relative expression.   
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chloride (Tocris Bioscience) was prepared as a 5 mg/ml 
stock solution in water. 
 
siRNA transfection. Cells were seeded at 200,000 cells 
per well in 6-well plates (for RNA isolation), or at 
700,000 cells per 6-cm dish (for protein extraction) in 
antibiotic free DMEM containing 1% BGS in a small 
volume.  Cells were reverse transfected with 100 nM 
siRNA (Dharmacon Research, Inc.) at time of seeding 
using Lipofectamine 2000 (Invitrogen).  After a five 
hour incubation, the media was removed and cells were 
refed with DMEM containing 10% BGS.  Twenty hours 
later, the cells were transfected again with 100 nM 
siRNA in a small volume of serum free media using 
Oligofectamine (Invitrogen).  After a four-hour 
incubation, an equal volume of DMEM containing 20% 
BGS was added to each well or dish without removing 
the transfection mixture.  Total RNA was isolated 24 
hours post siRNA transfection and protein was 
extracted at 48 hours post siRNA unless otherwise 
indicated.  
 
Analysis of Affymetrix GeneChips. The Affymetrix 
HG-U133 plus 2.0 GeneChips containing probe sets 
detecting over 54,000 transcripts were used in this study 
and each transfection condition was performed in 
triplicate. GeneChip cel files were imported into 
GeneSpring GX and preprocessed by GCRMA.  
Measurements less than 0.01 were then set to 0.01, and 
each chip was normalized to the 50th percentile of the 
measurements taken from that chip.  Extra background 
correction was never applied.  Each gene was 
normalized to the median of the measurements for that 
gene, and then to the median of that gene’s expression 
in the siCon condition.  
  
Initially all genes were filtered in GeneSpring GX first 
by Welch ANOVA to find expression changes based on 
siRNA treatment, using a p-value cut off of 0.05 and the 
Benjamini and Hochberg False Discovery Rate as a 
multiple testing correction.  The cross-gene error model 
was active and based on replicates.  From this list, genes 
were removed which varied between the mock and 
siCon treatments by 1.5 fold with a p-value < 0.05.  
Next, lists of genes with expression changes of 1.5 fold 
and a p-value < 0.05 were then made for siHdm2 versus 
siCon and siHdmX versus siCon.  We then eliminated 
all but the union between these two lists.  One gene that 
was repressed in the siHdm2 condition but upregulated 
in the siHdmX condition (encoding hypothetical protein 
MGC5370) was manually removed.   Finally, genes that 
were not changed 1.5 fold with a p-value of <0.05 
between the siHdmX and siHdmX + sip53 conditions 
were removed leaving a total of 394 selected genes.   
 
Quantitative RT-pPCR. Cells were lysed directly in the 
culture dish and total RNA was isolated using the 
RNeasy kit (Qiagen) according to manufacturer’s 
protocol.  The RNA was quantified by spectrophoto-
meter reading at 260 nm, and 1 µg RNA was reverse 
transcribed with random hexamers to create cDNA 
using the TaqMan Reverse transcription kit (Applied 
Biosystems).  Quantitative PCR was performed in a 96-
well micro titer plate format on an ABI Prism 7900HT 
sequence detection system using 1 µl cDNA, TaqMan 
Universal PCR master mix and Assay-on-Demand Gene 
Expression products (Applied Biosystems) specific for 
genes of interest.  Each cDNA sample was analyzed in 
triplicate and fold change relative to control was 
calculated based on a PCR efficiency of two and 
normalized to GAPDH (endogenous control) RNA 
levels.  Average fold change and standard deviation 
were obtained from 2-3 biological replicate samples per 
treatment assayed in triplicate.   
 
Western blot analysis. Frozen cells were lysed in an 
aqueous extraction buffer composed of 120 mM NaCl, 
50 mM Tris-HCl (pH 8.0), 5 mM EGTA, 1 mM EDTA, 
5 mM NaPPi, 10 mM NaF, 30 mM para-
nitrophenylphosphate, 1 mM Benzamidine, 0.1% NP-40 
(Ipegal Ca-630), 0.2 mM PMSF, and 1% protease 
inhibitor cocktail (Sigma), and soluble protein was 
recovered by centrifugation. Protein concentration was 
determined using Bradford reagent (Bio-Rad), and 
proteins were resolved on a sodium dodecyl sulfate-
10% polyacrylamide gel followed by transfer of 
proteins to a polyvinylidene difluoride membrane 
(Millipore) using a Transblot system (Bio-Rad).  
Immunoblotting was performed as previously described 
[52] using appropriate primary antibodies at 1:1000-
1:10,000 dilution and secondary antibodies (goat anti-
mouse or goat anti-rabbit HRP-conjugated, Promega) at 
1:5000-1:10,000 dilution.  Blots were exposed to 
chemiluminescent reagent (Pierce) and protein was 
visualized on a FUJIFILM LAS-3000 image reader. 
 
Colony formation and cell viability assays. Twenty-four 
hours after the second siRNA transfection, the cells 
were trypsinized, counted and seeded at 500 cells per 
well in 6-well plates for the colony formation assay.  
The cells were allowed to grow for ten days, and then 
the colonies were fixed and stained in 1% crystal violet 
in 70% methanol.  The cell viability assays were 
performed in 96-well plates using either CellQuanti-
Blue™ Reagent (BioAssay Systems) according to 
manufacturer’s protocol or by staining the cells with 
crystal violet, extracting the stain in 10% acetic acid, 
and then reading absorbance at 590 nm.  Again, cells 
were trypsinized after the second siRNA transfection, 
counted and seeded at 20,000 cells per well.  Cell 
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viability was determined at various time points post-
seeding or following treatment with chemotherapeutic 
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